Funded Biotechnology Startups in Switzerland
Switzerland's biotechnology funding activity across these 50 rounds spans late 2023 through November 2025, with geographic weight concentrated in three cor…
Switzerland's biotechnology funding activity across these 50 rounds spans late 2023 through November 2025, with geographic weight concentrated in three corridors: the Vaud canton anchored by Lausanne, the Basel metropolitan area, and greater Zürich including Schlieren. Lausanne produced a notable cluster — ReproNovo and HAYA Therapeutics each closed $65M Series A rounds in May 2025, and Timeline raised a $65M Series D in January 2024.
The two largest disclosed amounts sit outside Lausanne: Pharvaris raised $201M in July 2025 from Zug, and Noema Pharma closed a $147M Series B in December 2024 from Basel. Round size spans widely, from $30K pre-seeds at DropGen (Basel) and SensArs (Lausanne) to nine-figure transactions. "Series Unknown" is the most frequent stage designation, appearing across companies of varied maturity — from sub-$1M closes like Calico Biosystems ($170K) to the Pharvaris raise.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
The five largest are Pharvaris at $201M (Zug, July 2025), Noema Pharma at $147M Series B (Basel, December 2024), Nouscom at $83M (Basel, March 2024), MoonLake Immunotherapeutics at $75M (Zug, April 2025), and Granite Bio at $70M Series B (Basel, April 2025).
Which Swiss cities account for the most biotech funding activity here?
Lausanne and its Vaud neighbors lead in deal count, with Lausanne proper appearing in at least a dozen entries including HAYA Therapeutics, ReproNovo, AC Immune, and Timeline. Basel and adjacent suburbs — Schlieren, Allschwil — cluster a second group that includes Noema Pharma, Granite Bio, ImmunOs Therapeutics, LimmaTech Biologics, and Nouscom.
Were there any notable clusters of simultaneous closes?
May 2025 saw ReproNovo and HAYA Therapeutics both close $65M Series A rounds in Lausanne within two weeks of each other. April 2025 had back-to-back activity as well: MoonLake ($75M) and SamanTree Medical ($6M Series B) both closed on April 3, and Bloom Biorenewables closed a $15M Series A on April 2.
How does early-stage Swiss biotech activity compare to growth-stage in this data?
Growth-stage rounds dominate by dollar amount — Granite Bio ($70M Series B) and Noema Pharma ($147M Series B) anchor the upper end — but seed and pre-seed rounds are present, including arcoris bio's $8M seed in Schlieren (November 2025), Hemostod's $5M seed in Lausanne (October 2025), and four pre-seed rounds, the largest being NXI Therapeutics at $4M (Basel, June 2024).
What stage labels appear most often among Swiss biotech rounds here?
"Series Unknown" is the most frequent designation, spanning from sub-$1M closes like iOnctura ($400K) and Aspivix ($560K) up to Pharvaris at $201M — likely reflecting secondary offerings, convertible structures, or undisclosed vehicle types. Named stages include six seed rounds, four Series A, five Series B, two Series C, and one Series D (Timeline, $65M, January 2024).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.